[go: up one dir, main page]

SI3291679T1 - Predrugačenje mikrobnih populacij in spreminjanje mikrobiote - Google Patents

Predrugačenje mikrobnih populacij in spreminjanje mikrobiote

Info

Publication number
SI3291679T1
SI3291679T1 SI201631431T SI201631431T SI3291679T1 SI 3291679 T1 SI3291679 T1 SI 3291679T1 SI 201631431 T SI201631431 T SI 201631431T SI 201631431 T SI201631431 T SI 201631431T SI 3291679 T1 SI3291679 T1 SI 3291679T1
Authority
SI
Slovenia
Prior art keywords
microbial populations
altering microbial
modifying microbiota
microbiota
modifying
Prior art date
Application number
SI201631431T
Other languages
English (en)
Inventor
Jasper Clube
Morten Sommer
Christian Grondahl
Der Helm Eric Van
Ruben Vazquez-Uribe
Original Assignee
Snipr Technologies Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57217569&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3291679(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1507774.6A external-priority patent/GB201507774D0/en
Priority claimed from GBGB1507775.3A external-priority patent/GB201507775D0/en
Priority claimed from GBGB1507773.8A external-priority patent/GB201507773D0/en
Priority claimed from GBGB1507776.1A external-priority patent/GB201507776D0/en
Priority claimed from GBGB1508461.9A external-priority patent/GB201508461D0/en
Priority claimed from GBGB1509366.9A external-priority patent/GB201509366D0/en
Priority claimed from GBGB1510891.3A external-priority patent/GB201510891D0/en
Priority claimed from GBGB1518402.1A external-priority patent/GB201518402D0/en
Priority claimed from GBGB1600418.6A external-priority patent/GB201600418D0/en
Priority claimed from GB1600417.8A external-priority patent/GB2531454A/en
Application filed by Snipr Technologies Limited filed Critical Snipr Technologies Limited
Publication of SI3291679T1 publication Critical patent/SI3291679T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/20—Bacteria; Substances produced thereby or obtained therefrom
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/50—Isolated enzymes; Isolated proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/60—Isolated nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pest Control & Pesticides (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Agronomy & Crop Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
SI201631431T 2015-05-06 2016-05-03 Predrugačenje mikrobnih populacij in spreminjanje mikrobiote SI3291679T1 (sl)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
GBGB1507775.3A GB201507775D0 (en) 2015-05-06 2015-05-06 Products, uses & methods (3)
GBGB1507773.8A GB201507773D0 (en) 2015-05-06 2015-05-06 Products, uses & methods (1)
GBGB1507776.1A GB201507776D0 (en) 2015-05-06 2015-05-06 Products, uses & methods (4)
GBGB1507774.6A GB201507774D0 (en) 2015-05-06 2015-05-06 Products, uses & methods (2)
GBGB1508461.9A GB201508461D0 (en) 2015-05-17 2015-05-17 Products uses and methods (4.2)
GBGB1509366.9A GB201509366D0 (en) 2015-05-31 2015-05-31 Products, uses & methods (6)
GBGB1510891.3A GB201510891D0 (en) 2015-06-20 2015-06-20 Products, uses & methods (7)
GBGB1518402.1A GB201518402D0 (en) 2015-10-17 2015-10-17 Products, uses & methods (8)
GBGB1600418.6A GB201600418D0 (en) 2016-01-10 2016-01-10 Products, uses & methods (1.2)
GB1600417.8A GB2531454A (en) 2016-01-10 2016-01-10 Recombinogenic nucleic acid strands in situ
EP16719873.8A EP3291679B1 (en) 2015-05-06 2016-05-03 Altering microbial populations & modifying microbiota
PCT/EP2016/059803 WO2016177682A1 (en) 2015-05-06 2016-05-03 Altering microbial populations & modifying microbiota

Publications (1)

Publication Number Publication Date
SI3291679T1 true SI3291679T1 (sl) 2022-04-29

Family

ID=57217569

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201631431T SI3291679T1 (sl) 2015-05-06 2016-05-03 Predrugačenje mikrobnih populacij in spreminjanje mikrobiote

Country Status (17)

Country Link
US (30) US9701964B2 (sl)
EP (12) EP4169383A1 (sl)
JP (4) JP2018515138A (sl)
KR (4) KR102138209B1 (sl)
CN (2) CN114099712A (sl)
AU (5) AU2016257306B2 (sl)
CA (1) CA2984975A1 (sl)
DE (1) DE112016002056T5 (sl)
DK (1) DK3291679T3 (sl)
ES (1) ES2905525T3 (sl)
IL (4) IL293646B2 (sl)
NZ (1) NZ738068A (sl)
PL (1) PL3291679T3 (sl)
RU (1) RU2017142352A (sl)
SG (1) SG11201708706YA (sl)
SI (1) SI3291679T1 (sl)
WO (1) WO2016177682A1 (sl)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10548761B2 (en) 2011-02-04 2020-02-04 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
EP2734621B1 (en) 2011-07-22 2019-09-04 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
WO2014093701A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
CN110872583A (zh) 2012-12-12 2020-03-10 布罗德研究所有限公司 用于序列操纵和治疗应用的系统、方法和组合物的递送、工程化和优化
US10660943B2 (en) 2013-02-07 2020-05-26 The Rockefeller University Sequence specific antimicrobials
US11135273B2 (en) 2013-02-07 2021-10-05 The Rockefeller University Sequence specific antimicrobials
CN113425857B (zh) 2013-06-17 2025-05-16 布罗德研究所有限公司 用于肝靶向和治疗的crispr-cas系统、载体和组合物的递送与用途
EP3011033B1 (en) 2013-06-17 2020-02-19 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
EP4245853A3 (en) 2013-06-17 2023-10-18 The Broad Institute, Inc. Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US10584358B2 (en) 2013-10-30 2020-03-10 North Carolina State University Compositions and methods related to a type-II CRISPR-Cas system in Lactobacillus buchneri
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
CN111206032B (zh) 2013-12-12 2024-07-19 布罗德研究所有限公司 用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用
JP6793547B2 (ja) 2013-12-12 2020-12-02 ザ・ブロード・インスティテュート・インコーポレイテッド 最適化機能ＣＲＩＳＰＲ−Ｃａｓ系による配列操作のための系、方法および組成物
WO2015089364A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Crystal structure of a crispr-cas system, and uses thereof
MX2016007325A (es) 2013-12-12 2017-07-19 Broad Inst Inc Composiciones y metodos de uso de sistemas crispr-cas en desordenes debidos a repeticion de nucleotidos.
EP4219699A1 (en) 2013-12-12 2023-08-02 The Broad Institute, Inc. Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
SG10201804975PA (en) 2013-12-12 2018-07-30 Broad Inst Inc Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for HBV and Viral Diseases and Disorders
US10787654B2 (en) 2014-01-24 2020-09-29 North Carolina State University Methods and compositions for sequence guiding Cas9 targeting
US11439712B2 (en) 2014-04-08 2022-09-13 North Carolina State University Methods and compositions for RNA-directed repression of transcription using CRISPR-associated genes
CA2956224A1 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
US10450584B2 (en) 2014-08-28 2019-10-22 North Carolina State University Cas9 proteins and guiding features for DNA targeting and genome editing
EP3230451B1 (en) 2014-12-12 2021-04-07 The Broad Institute, Inc. Protected guide rnas (pgrnas)
CA2970370A1 (en) 2014-12-24 2016-06-30 Massachusetts Institute Of Technology Crispr having or associated with destabilization domains
KR102138209B1 (ko) 2015-05-06 2020-07-28 스니프르 테크놀로지스 리미티드 미생물 개체군 변경 및 미생물군 변형
HK1253712A1 (zh) * 2015-05-29 2019-06-28 North Carolina State University 使用crispr核酸筛选细菌、古细菌、藻类和酵母的方法
US11155823B2 (en) * 2015-06-15 2021-10-26 North Carolina State University Methods and compositions for efficient delivery of nucleic acids and RNA-based antimicrobials
JP7107683B2 (ja) 2015-06-18 2022-07-27 ザ・ブロード・インスティテュート・インコーポレイテッド オフターゲット効果を低下させるｃｒｉｓｐｒ酵素突然変異
WO2016205759A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
WO2017058751A1 (en) 2015-09-28 2017-04-06 North Carolina State University Methods and compositions for sequence specific antimicrobials
IL258821B (en) 2015-10-23 2022-07-01 Harvard College Nucleobase editors and their uses
WO2017112620A1 (en) 2015-12-22 2017-06-29 North Carolina State University Methods and compositions for delivery of crispr based antimicrobials
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
EP3494215A1 (en) 2016-08-03 2019-06-12 President and Fellows of Harvard College Adenosine nucleobase editors and uses thereof
AU2017308889B2 (en) 2016-08-09 2023-11-09 President And Fellows Of Harvard College Programmable Cas9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
GB2573062A (en) 2016-10-14 2019-10-23 Harvard College AAV delivery of nucleobase editors
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
US12390514B2 (en) 2017-03-09 2025-08-19 President And Fellows Of Harvard College Cancer vaccine
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
EP3592777A1 (en) 2017-03-10 2020-01-15 President and Fellows of Harvard College Cytosine to guanine base editor
EP3601562A1 (en) 2017-03-23 2020-02-05 President and Fellows of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
US11267738B2 (en) * 2017-04-24 2022-03-08 Microbe Detectives Llc Method of using microbial DNA sequencing in recovering renewable resources from wastewater and other waste streams
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
WO2019002218A2 (en) 2017-06-25 2019-01-03 Snipr Technologies Limited MODIFICATION OF MICROBIAL POPULATIONS AND MODIFICATION OF MICROBIOTA
GB201710126D0 (en) 2017-06-25 2017-08-09 Snipr Tech Ltd Vectors & Methods
EP3651796A4 (en) * 2017-07-12 2021-06-30 The Brigham and Women's Hospital, Inc. LIVE ATTENUATED CHOLERA VACCINE WITH PROBIOTIC PROPERTIES
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
GB201712733D0 (en) * 2017-08-08 2017-09-20 Snipr Tech Ltd Methods & cells
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
WO2019055582A1 (en) * 2017-09-12 2019-03-21 Ubabiologix Corp. COMPOSITIONS AND METHODS FOR SANITATION OF WASTE WATER
WO2019079347A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. USES OF BASIC EDITORS ADENOSINE
JP7522656B2 (ja) 2017-11-21 2024-07-25 クリスパー セラピューティクス アーゲー 常染色体優性網膜色素変性の処置のための材料および方法
JP7460531B2 (ja) 2017-12-05 2024-04-02 バイオピーエルエックス，インコーポレイティド 微生物感染を防ぐための方法および組成物
CN109899053B (zh) * 2017-12-08 2022-02-01 中国石油天然气股份有限公司 钻井井场的确定方法、装置及计算机可读存储介质
EP3724214A4 (en) 2017-12-15 2021-09-01 The Broad Institute Inc. SYSTEMS AND METHODS FOR PREDICTING REPAIR RESULTS IN GENETIC ENGINEERING
CN109971778B (zh) * 2017-12-27 2022-11-18 北京蓝晶微生物科技有限公司 一种在盐单胞菌中快速基因编辑的载体组合及其应用
CN108410880B (zh) * 2018-01-26 2021-10-22 昆明理工大学 一种丹波黑大豆柠檬酸转运蛋白基因及其应用
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
BR112020019418A2 (pt) 2018-03-25 2021-02-17 Snipr Biome Aps. tratamento e prevenção de infecções microbianas
EP3788152A4 (en) 2018-05-04 2022-03-09 Locus Biosciences, Inc. METHODS AND COMPOSITIONS FOR KILLING A TARGET BACTERIA
CN112941155B (zh) * 2018-05-14 2023-07-14 北京艾克伦医疗科技有限公司 具有茎环结构的dna引物对及其应用
EP3797160A1 (en) 2018-05-23 2021-03-31 The Broad Institute Inc. Base editors and uses thereof
WO2019227080A1 (en) * 2018-05-25 2019-11-28 Locus Biosciences, Inc. Methods and compositions for killing a target bacterium
JP2021531039A (ja) * 2018-07-11 2021-11-18 ソシエテ ドゥ コメルシアリサション デ プロドゥイ ドゥ ラ ルシェルシェ アプリケ ソクプラ シアンス サンテ エ ユメーヌ エス．ウ．セ． 細菌接合システム及びその治療的使用
CN109136128B (zh) * 2018-08-23 2021-07-16 国家海洋局第一海洋研究所 一种副球菌及其筛选方法和在合成银纳米颗粒中的应用
US12144834B2 (en) 2018-09-13 2024-11-19 Xbiome Inc. Methods and compositions for treating gastrointestinal and inflammatory disorders
US12264330B2 (en) 2018-10-01 2025-04-01 North Carolina State University Recombinant type I CRISPR-Cas system and uses thereof for killing target cells
US12203123B2 (en) 2018-10-01 2025-01-21 North Carolina State University Recombinant type I CRISPR-Cas system and uses thereof for screening for variant cells
EP3861120A4 (en) 2018-10-01 2023-08-16 North Carolina State University Recombinant type i crispr-cas system
US12264313B2 (en) 2018-10-01 2025-04-01 North Carolina State University Recombinant type I CRISPR-Cas system and uses thereof for genome modification and alteration of expression
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
CN111119818B (zh) * 2018-10-30 2022-04-12 中国石油化工股份有限公司 一种油藏内源功能微生物定向调控的方法
WO2020146888A1 (en) * 2019-01-11 2020-07-16 The Trustees Of Columbia University In The City Of New York Microbiome engineering through engineered mobile genetic elements
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
GB201901099D0 (en) 2019-01-27 2019-03-13 Snipr Biome Aps Methods, uses and compositions
WO2020176624A1 (en) * 2019-02-26 2020-09-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Probiotics and probiotic compositions having modified carbohydrate metabolism
AU2020232850A1 (en) * 2019-03-07 2021-10-07 The Trustees Of Columbia University In The City Of New York RNA-guided DNA integration using Tn7-like transposons
WO2020191241A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
EP3956349A1 (en) 2019-04-17 2022-02-23 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
CN110499353B (zh) * 2019-08-09 2023-11-07 佛山市第四人民医院(佛山市结核病防治所) 一种用于结核耐药诊断的微生物标志物及其应用
GB201913045D0 (en) * 2019-09-10 2019-10-23 Univ Oxford Innovation Ltd Biofilm transformation
CN110596364B (zh) * 2019-09-12 2020-06-23 江南大学 一种前列腺特异性抗原检测的比率电化学传感器的构建方法及其应用
EP4031155A4 (en) * 2019-09-18 2023-10-18 Ancilia, Inc. Compositions and methods for microbiome modulation
WO2021067291A1 (en) * 2019-09-30 2021-04-08 Sigma-Aldrich Co. Llc Modulation of microbiota compositions using targeted nucleases
WO2021072328A1 (en) 2019-10-10 2021-04-15 The Broad Institute, Inc. Methods and compositions for prime editing rna
CN114981408A (zh) * 2019-11-06 2022-08-30 洛可斯生物科学公司 Crispr cas系统和溶原性模块
CA3162622A1 (en) * 2019-11-25 2021-06-03 Baylor College Of Medicine Selective expansion of gene-targeted cells
US20230046246A1 (en) * 2019-12-13 2023-02-16 The Regents Of The University Of California Reducing Antibiotic Resistance in Bacteria Using Pro-Active Genetics
DE102020101859A1 (de) * 2020-01-27 2021-07-29 Oxana Karpf Verfahren zur Reduktion der Population mindestens einer adipogenen Bakterienart umfassend Bakteriophagen sowie Bakteriophagen und deren Verwendung
US20230114119A1 (en) * 2020-03-16 2023-04-13 Cornell University COMPOSITIONS AND METHODS COMPRISING IMPROVED GUIDE RNAs
US20230147495A1 (en) * 2020-03-27 2023-05-11 Phuc Hong Vo Genome engineering using crispr rna-guided integrases
JP7527830B2 (ja) * 2020-04-16 2024-08-05 旭化成株式会社 セルロース繊維乾燥体の製造方法、及び樹脂複合体の製造方法
JP7488096B2 (ja) * 2020-04-16 2024-05-21 旭化成株式会社 セルロース繊維乾燥体及びその製造方法、並びに樹脂複合体の製造方法
JP7504650B2 (ja) * 2020-04-16 2024-06-24 旭化成株式会社 セルロース繊維乾燥体及びその製造方法、並びに樹脂複合体の製造方法
KR20230019843A (ko) 2020-05-08 2023-02-09 더 브로드 인스티튜트, 인코퍼레이티드 표적 이중 가닥 뉴클레오티드 서열의 두 가닥의 동시 편집을 위한 방법 및 조성물
WO2021231689A1 (en) * 2020-05-14 2021-11-18 Chan Zuckerberg Biohub, Inc. Phage-mediated delivery of genes to gut microbiome
GB202007943D0 (en) 2020-05-27 2020-07-08 Snipr Biome Aps Products & methods
EP3922719A1 (en) * 2020-06-12 2021-12-15 Eligo Bioscience Specific decolonization of antibiotic resistant bacteria for prophylactic purposes
WO2021257604A1 (en) * 2020-06-16 2021-12-23 Dsm Ip Assets B.V. A composition for reducing the risk of urinary tract infection and vaginal infection in women
CN111849822A (zh) * 2020-07-28 2020-10-30 上海海洋大学 对抗菌素敏感的非o1/o139型霍乱弧菌菌株及应用
CA3186252A1 (en) * 2020-08-06 2022-02-10 Tadas S. Sileika Bacteria formulation and products including same
WO2022081428A1 (en) * 2020-10-16 2022-04-21 Nubiyota Llc Bacterial compositions and methods of use thereof for treatment of metabolic syndrome
CN113201531B (zh) * 2021-04-27 2023-06-27 隆平生物技术(海南)有限公司 转基因玉米事件lw2-1及其检测方法
FR3136482A1 (fr) * 2021-08-01 2023-12-15 Snipr Biome Aps Ingenierie du microbiote
EP4381061A1 (en) * 2021-08-02 2024-06-12 Trobix Bio Ltd Systems for modulating drug metabolism by cells, methods and compositions thereof
US12406364B2 (en) 2022-02-15 2025-09-02 10X Genomics, Inc. Systems and methods for spatial analysis of analytes using fiducial alignment
CN114591879B (zh) * 2022-05-11 2022-12-06 中国农业大学 一种抑制幽门螺杆菌的发酵乳杆菌及其应用
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
WO2024003301A1 (en) 2022-06-29 2024-01-04 Snipr Biome Aps Targeting e coli cells
WO2024023820A1 (en) * 2022-07-25 2024-02-01 Trobix Bio Ltd Systems for modulating microbiome target cells, methods and compositions thereof
WO2024086532A1 (en) * 2022-10-17 2024-04-25 Locus Biosciences, Inc. Staphylococcus phage compositions and cocktails thereof
CN116042450B (zh) * 2022-11-03 2024-10-01 杭州秀川科技有限公司 一株高效降解苯胺类物质的陶厄氏菌及其应用
CN116058432B (zh) * 2023-03-02 2023-06-16 莱芜泰禾生化有限公司 一种柠檬酸菌丝渣微生物饲料添加剂及其制备方法和应用
CN116694535B (zh) * 2023-07-20 2024-08-23 四川大学 一种戊糖乳杆菌w19及其应用
WO2025046062A1 (en) 2023-08-31 2025-03-06 Snipr Biome Aps A novel type of crispr/cas system
WO2025093778A1 (en) * 2023-11-05 2025-05-08 Human Biome Institute S.A. Functional compositions and methods of use thereof in eradication and/or decolonization of antibiotic-resistant bacteria and restoration of healthy microbiota
JPWO2025100495A1 (sl) * 2023-11-09 2025-05-15
WO2025132815A1 (en) 2023-12-20 2025-06-26 Novozymes A/S Novel cas nucleases and polynucleotides encoding the same

Family Cites Families (212)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US928A (en) * 1838-09-19 Eccentbic bbake eob abbesting the motion of bailboad-cabs
US3003323A (en) 1958-01-29 1961-10-10 Armco Steel Corp Composite pile connector
US4626504A (en) 1983-07-01 1986-12-02 Lubrizol Genetics, Inc. DNA transfer vector for gram-negative bacteria
SE8505027D0 (sv) 1985-10-24 1985-10-24 Kabigen Ab A lytic virulent phage, a hostcell containing same and a process for protein production
US4870287A (en) 1988-03-03 1989-09-26 Loma Linda University Medical Center Multi-station proton beam therapy system
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
DE4208785A1 (de) 1992-03-19 1993-09-23 Degussa Verfahren zum auffinden von insertionselementen (is-elemente) oder transposonen
EP0665852A1 (en) 1993-07-09 1995-08-09 Amgen Boulder Inc. Recombinant ctla4 polypeptides and methods for making the same
US5760395A (en) 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
US5844905A (en) 1996-07-09 1998-12-01 International Business Machines Corporation Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange
AU6703198A (en) 1997-03-21 1998-10-20 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
US20030049841A1 (en) 1997-06-16 2003-03-13 Short Jay M. High throughput or capillary-based screening for a bioactivity or biomolecule
EP2112166B1 (en) 1998-12-23 2018-11-21 Pfizer Inc. Human monoclonal antibodies to ctla-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
AU784012B2 (en) 1999-08-24 2006-01-12 E. R. Squibb & Sons, L.L.C. Human CTLA-4 antibodies and their uses
AU2001249050A1 (en) 2000-01-11 2001-07-24 Intralytix, Inc. Reduction in bacterial colonization by administering bacteriophage compositions
AU2002365188A1 (en) 2001-11-07 2003-07-30 Musc Foundation For Research Development Nucleic acid delivery and expression
CA2396611A1 (en) 2002-07-31 2004-01-31 Plant Bioscience Limited Materials and methods for generating genetic disruptions in bacterial cells
ES2725526T3 (es) 2003-07-02 2019-09-24 Innate Pharma Anticuerpos del receptor de NK pan-kir2dl y su uso en diagnóstico y terapia
KR20060038461A (ko) 2003-07-24 2006-05-03 이나뜨 파르마 Ｎｋ 세포 강화 화합물을 사용하여 치료용 항체의 효율을높이는 방법 및 조성물
US20070020240A1 (en) 2003-10-06 2007-01-25 Gangagen, Inc. Defined dose therapeutic phage
US20090155768A1 (en) 2004-04-07 2009-06-18 Dean Scholl Reporter plasmid phage packaging system for detection of bacteria
CN1997670B (zh) 2004-07-01 2014-04-30 诺和诺德公司 人类抗-kir抗体
JP5855326B2 (ja) 2005-01-06 2016-02-09 ノヴォ ノルディスク アー／エス 抗ｋｉｒ組み合わせ治療および方法
US8222376B2 (en) 2005-01-06 2012-07-17 Novo Nordisk A/S KIR-binding agents and methods of use thereof
CN117534755A (zh) 2005-05-09 2024-02-09 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
DK3284833T3 (da) 2005-08-26 2022-02-07 Dupont Nutrition Biosci Aps Anvendelse af crispr-associerede gener (cas)
WO2007042573A2 (en) 2005-10-14 2007-04-19 Innate Pharma Compositions and methods for treating proliferative disorders
EP2468765B1 (en) 2006-03-03 2015-04-22 ONO Pharmaceutical Co., Ltd. Tetramer of extracellular domain of PD-L1
US8445639B2 (en) 2006-05-15 2013-05-21 Avidbiotics Corporation Recombinant bacteriophage and methods for their use
EP2102350A4 (en) * 2006-12-18 2012-08-08 Univ St Louis DARMMICROBIOMA AS A BIOMARKER AND THERAPEUTIC OBJECT FOR THE TREATMENT OF ADIPOSITAS OR ADIPOSITASCONDUCTIVE DISEASES
WO2008084106A1 (en) 2007-01-11 2008-07-17 Novo Nordisk A/S Anti-kir antibodies, formulations, and uses thereof
RU2531343C2 (ru) 2007-03-02 2014-10-20 ДюПон Ньютришн Байосайенсиз АпС, Способ генерирования заквасочной культуры, заквасочная культура и способ ферментации с ее использованием
EP2145015A4 (en) 2007-03-30 2012-02-29 Ca Nat Research Council PHAGE RECEPTOR BINDING PROTEINS FOR ANTIBACTERIAL THERAPY AND OTHER NEW USES
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
PL2170959T3 (pl) 2007-06-18 2014-03-31 Merck Sharp & Dohme Przeciwciała przeciwko ludzkiemu receptorowi programowanej śmierci PD-1
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
HUE034465T2 (en) 2008-02-11 2018-02-28 Cure Tech Ltd Monoclonal antibodies for tumor treatment
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
US8546553B2 (en) 2008-07-25 2013-10-01 University Of Georgia Research Foundation, Inc. Prokaryotic RNAi-like system and methods of use
US8119129B2 (en) 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US20110159023A1 (en) 2008-08-25 2011-06-30 Solomon Langermann Pd-1 antagonists and methods for treating infectious disease
US20100076057A1 (en) 2008-09-23 2010-03-25 Northwestern University TARGET DNA INTERFERENCE WITH crRNA
EP2367553B1 (en) 2008-12-05 2017-05-03 Novo Nordisk A/S Combination therapy to enhance nk cell mediated cytotoxicity
JP5344895B2 (ja) * 2008-12-10 2013-11-20 矢崎総業株式会社 充電監視装置
WO2010075424A2 (en) 2008-12-22 2010-07-01 The Regents Of University Of California Compositions and methods for downregulating prokaryotic genes
US8241498B2 (en) 2009-03-28 2012-08-14 Phage Biocontrol Research, Llc Process for remediating biofouling in water systems with virulent bacteriophage
JP2010285425A (ja) 2009-05-12 2010-12-24 Fujifilm Corp 腸内細菌叢構成比率調整剤
WO2011014438A1 (en) 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla
CN102741279A (zh) 2009-08-31 2012-10-17 艾普利穆恩公司 B7-h4融合蛋白和其使用方法
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
ES2586579T3 (es) 2010-02-19 2016-10-17 Xencor, Inc. Nuevas inmunoadhesinas de CTLA4-IG
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US8252576B2 (en) 2010-08-11 2012-08-28 Phage Biocontrol Research, Llc Use of prokaryote viruses to remediate bio-fouling
CN103261213A (zh) * 2010-10-20 2013-08-21 杜邦营养生物科学有限公司 乳球菌CRISPR-Cas序列
TWI664191B (zh) 2010-11-22 2019-07-01 天賜製藥公司 Ｎｋ細胞調節治療及治療血液惡性疾病之方法
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US10835560B2 (en) 2013-12-20 2020-11-17 Joseph E. Kovarik Reducing the likelihood of skin cancer in an individual human being
US9730967B2 (en) 2011-02-04 2017-08-15 Katherine Rose Kovarik Method and system for treating cancer cachexia
US10245288B2 (en) 2011-02-04 2019-04-02 Joseph E. Kovarik Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
US20180099001A1 (en) 2011-04-29 2018-04-12 Volant Holdings Gmbh Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof
WO2012159023A2 (en) 2011-05-19 2012-11-22 Virginia Commonwealth University Gut microflora as biomarkers for the prognosis of cirrhosis and brain dysfunction
TWI560200B (en) 2011-05-25 2016-12-01 Innate Pharma Sa Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders
WO2012164565A1 (en) 2011-06-01 2012-12-06 Yeda Research And Development Co. Ltd. Compositions and methods for downregulating prokaryotic genes
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
CA2845536A1 (en) 2011-08-15 2013-02-21 Amplimmune, Inc. Anti-b7-h4 antibodies and their uses
WO2013025119A1 (ru) 2011-08-18 2013-02-21 Roschin Evgeniy Mikhailovich Способ определения расположения протетической верхней плоскости у пациентов
US20130121968A1 (en) 2011-10-03 2013-05-16 Atossa Genetics, Inc. Methods of combining metagenome and the metatranscriptome in multiplex profiles
PT3424947T (pt) 2011-10-28 2021-03-01 Regeneron Pharma Ratinhos com recetores de células t geneticamente modificados
WO2013067492A1 (en) 2011-11-03 2013-05-10 The Trustees Of The University Of Pennsylvania Isolated b7-h4 specific compositions and methods of use thereof
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
CA2871265C (en) 2012-04-30 2021-07-13 Sonomaceuticals, Llc Therapeutic use of chardonnay seed products
AU2013263076B2 (en) 2012-05-15 2017-08-31 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
LT2800811T (lt) 2012-05-25 2017-09-11 The Regents Of The University Of California Būdai ir kompozicijos, skirti tikslinės dnr modifikavimui, panaudojant adresuotą rnr, ir transkripcijos moduliavimui, panaudojant adresuotą rnr
WO2013187556A1 (en) 2012-06-14 2013-12-19 Scripps Korea Antibody Institute Novel antibody specific for clec14a and uses thereof
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
US10025647B2 (en) 2012-06-30 2018-07-17 Intel Corporation Memory poisoning with hints
IN2015DN00139A (sl) 2012-07-13 2015-06-12 Univ Pennsylvania
JP2014022858A (ja) 2012-07-17 2014-02-03 Murata Mfg Co Ltd 電力増幅器
US9460205B2 (en) * 2012-07-20 2016-10-04 Google Inc. Crowdsourced video collaboration
CN105188767A (zh) 2012-07-25 2015-12-23 布罗德研究所有限公司 可诱导的dna结合蛋白和基因组干扰工具及其应用
AU2013312211B2 (en) 2012-09-07 2018-03-29 King's College London VISTA modulators for diagnosis and treatment of cancer
CA2884281C (en) 2012-09-11 2021-01-05 Thylabisco Ab Prebiotic thylakoid composition
AU2013315382A1 (en) 2012-09-13 2015-03-05 Salix Pharmaceuticals, Inc. Methods of administering rifaximin for weight loss and treatment of obesity
US11060148B2 (en) 2012-10-16 2021-07-13 Dana-Farber Cancer Institute, Inc. Diagnosing and treating colorectal cancer
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
BR122021008308B1 (pt) 2012-12-12 2022-12-27 The Broad Institute, Inc. Sistemas de componente crispr-cas, métodos e composições para manipulação de sequência
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
EP2946015B1 (en) 2013-01-16 2021-05-26 Emory University Cas9-nucleic acid complexes and uses related thereto
US10660943B2 (en) 2013-02-07 2020-05-26 The Rockefeller University Sequence specific antimicrobials
US11135273B2 (en) * 2013-02-07 2021-10-05 The Rockefeller University Sequence specific antimicrobials
US9593339B1 (en) * 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
HK1220495A1 (zh) 2013-03-14 2017-05-05 Seres Therapeutics, Inc. 从材料和组合物中检测和富集病原体的方法
EP3620534B1 (en) 2013-03-14 2021-10-13 Caribou Biosciences, Inc. Crispr-cas compositions of nucleic acid-targeting nucleic acids
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
US20140349400A1 (en) 2013-03-15 2014-11-27 Massachusetts Institute Of Technology Programmable Modification of DNA
DK2981607T3 (da) 2013-04-03 2020-11-16 Memorial Sloan Kettering Cancer Center Effektiv generering af tumormålrettede t-celler afledt af pluripotente stamceller
EP4119662A1 (en) 2013-05-10 2023-01-18 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
EP4245853A3 (en) 2013-06-17 2023-10-18 The Broad Institute, Inc. Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
EP4023750A1 (en) 2013-07-01 2022-07-06 Massachusetts Institute of Technology Functionalization of endogenous bacteria
DE102013012448A1 (de) 2013-07-26 2015-01-29 Kuka Laboratories Gmbh Verfahren und Vorrichtung zum Bremsen einer Roboterachsanordnung
JP5729429B2 (ja) 2013-07-29 2015-06-03 トヨタ自動車株式会社 接合構造、及び接合構造の製造方法
AU2014296887A1 (en) 2013-08-02 2016-01-28 Aduro Biotech Holdings, Europe B.V. Combining CD27 agonists and immune checkpoint inhibition for immune stimulation
US20150044772A1 (en) 2013-08-09 2015-02-12 Sage Labs, Inc. Crispr/cas system-based novel fusion protein and its applications in genome editing
EP3041498B1 (en) 2013-09-05 2022-02-16 Massachusetts Institute of Technology Tuning microbial populations with programmable nucleases
US20150070747A1 (en) * 2013-09-09 2015-03-12 Qualcomm Mems Technologies, Inc. Display element reset using polarity reversal
KR102100419B1 (ko) 2013-09-13 2020-04-14 베이진 스위찰랜드 게엠베하 항-pd1 항체 및 이의 치료 및 진단 용도
ES2844174T3 (es) 2013-09-18 2021-07-21 Kymab Ltd Métodos, células y organismos
US20160237455A1 (en) * 2013-09-27 2016-08-18 Editas Medicine, Inc. Crispr-related methods and compositions
JP6417413B2 (ja) 2013-10-17 2018-11-07 ナショナル ユニヴァーシティー オブ シンガポール 多様な腫瘍に対する抗体依存性細胞毒性を誘発するキメラ受容体
US10144770B2 (en) 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
US10767156B2 (en) 2013-10-24 2020-09-08 Yeda Research And Development Co., Ltd. Polynucleotides encoding BREX system polypeptides and methods of using same
JP2016537418A (ja) 2013-11-05 2016-12-01 テンプル ユニバーシティー オブ ザ コモンウェルス システム オブ ハイアー エデュケーション 抗菌剤としてのポリカチオン両親媒性物質
WO2015069682A2 (en) 2013-11-05 2015-05-14 President And Fellows Of Harvard College Precise microbiota engineering at the cellular level
EP3363903B1 (en) 2013-11-07 2024-01-03 Editas Medicine, Inc. Crispr-related methods and compositions with governing grnas
US20150132263A1 (en) 2013-11-11 2015-05-14 Radiant Genomics, Inc. Compositions and methods for targeted gene disruption in prokaryotes
US20160298096A1 (en) 2013-11-18 2016-10-13 Crispr Therapeutics Ag Crispr-cas system materials and methods
EP2876167A1 (en) 2013-11-21 2015-05-27 Institut Gustave Roussy Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-,pro- or synbiotics) for improving the efficacy of a cancer treatment
US20150157670A1 (en) * 2013-12-06 2015-06-11 K&K Ventures, LLC Non-caloric probiotic composition and method of preparation
BR112016013400B1 (pt) 2013-12-11 2023-02-14 Regeneron Pharmaceuticals, Inc. Método in vitro para modificar um genoma em um lócus genômico de interesse em uma célula pluripotente
AU2014361826A1 (en) 2013-12-12 2016-06-23 Massachusetts Institute Of Technology Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for targeting disorders and diseases using particle delivery components
MX2016007325A (es) * 2013-12-12 2017-07-19 Broad Inst Inc Composiciones y metodos de uso de sistemas crispr-cas en desordenes debidos a repeticion de nucleotidos.
JP6755801B2 (ja) 2014-01-29 2020-09-16 シンファジェン・リミテッド・ライアビリティ・カンパニーＳｙｎＰｈａＧｅｎ ＬＬＣ． 治療的な使用のための、核酸送達のための治療用ファージおよび方法
US10287590B2 (en) 2014-02-12 2019-05-14 Dna2.0, Inc. Methods for generating libraries with co-varying regions of polynuleotides for genome modification
CN106687125B (zh) 2014-03-12 2021-12-14 耶达研究与开发有限公司 降低系统性调节性t细胞水平或活性来治疗cns疾病和损伤
JP6701088B2 (ja) 2014-03-19 2020-05-27 インフィニティー ファーマシューティカルズ， インコーポレイテッド Ｐｉ３ｋ−ガンマ媒介障害の治療で使用するための複素環式化合物
US20170173086A1 (en) 2014-03-25 2017-06-22 Ginkgo Bioworks, Inc. Methods and Genetic Systems for Cell Engineering
WO2015148863A2 (en) * 2014-03-26 2015-10-01 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating sickle cell disease
EP3126503A1 (en) 2014-04-03 2017-02-08 Massachusetts Institute Of Technology Methods and compositions for the production of guide rna
US11439712B2 (en) 2014-04-08 2022-09-13 North Carolina State University Methods and compositions for RNA-directed repression of transcription using CRISPR-associated genes
JP6849435B2 (ja) * 2014-04-14 2021-03-24 ネメシス バイオサイエンス リミティド 治療薬
GB201406970D0 (en) 2014-04-17 2014-06-04 Green Biologics Ltd Targeted mutations
GB201406968D0 (en) 2014-04-17 2014-06-04 Green Biologics Ltd Deletion mutants
US11584936B2 (en) 2014-06-12 2023-02-21 King Abdullah University Of Science And Technology Targeted viral-mediated plant genome editing using CRISPR /Cas9
MY188940A (en) 2014-07-11 2022-01-13 Ventana Med Syst Inc Anti-pd-l1 antibodies and diagnostic uses thereof
US10450584B2 (en) 2014-08-28 2019-10-22 North Carolina State University Cas9 proteins and guiding features for DNA targeting and genome editing
US11274317B2 (en) 2014-09-05 2022-03-15 Vilnius University Targeted RNA knockdown and knockout by type III-A Csm complexes
EP3659621A1 (en) 2014-09-13 2020-06-03 Novartis AG Combination therapies for cancer
KR20170083534A (ko) 2014-09-19 2017-07-18 리제너론 파마슈티칼스 인코포레이티드 키메라 항원 수용체
CA2966132A1 (en) 2014-10-23 2016-04-28 Institut Gustave Roussy Methods and products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker
EP3224353B9 (en) 2014-11-26 2023-08-09 Technology Innovation Momentum Fund (Israel) Limited Partnership Targeted elimination of bacterial genes
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
US20160244784A1 (en) 2015-02-15 2016-08-25 Massachusetts Institute Of Technology Population-Hastened Assembly Genetic Engineering
SG11201707025WA (en) 2015-03-02 2017-09-28 Synlogic Inc Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
EP3964234A1 (en) 2015-04-23 2022-03-09 Kaleido Biosciences, Inc. Glycan therapeutics and methods of treatment
KR102138209B1 (ko) 2015-05-06 2020-07-28 스니프르 테크놀로지스 리미티드 미생물 개체군 변경 및 미생물군 변형
GB2531454A (en) 2016-01-10 2016-04-20 Snipr Technologies Ltd Recombinogenic nucleic acid strands in situ
EP3294757B1 (en) 2015-05-13 2023-12-27 Synlogic Operating Company, Inc. Bacteria engineered to treat a disease or disorder
EP3882259A1 (en) 2015-05-13 2021-09-22 Synlogic Operating Company, Inc. Bacteria engineered to reduce hyperphenylalaninemia
US11883439B2 (en) 2015-05-13 2024-01-30 Synlogic Operating Company, Inc. Bacteria engineered to treat a disease or disorder
US20160347836A1 (en) 2015-05-28 2016-12-01 Bristol-Myers Squibb Company Treatment of hodgkin's lymphoma using an anti-pd-1 antibody
HK1253712A1 (zh) 2015-05-29 2019-06-28 North Carolina State University 使用crispr核酸筛选细菌、古细菌、藻类和酵母的方法
MA43344A (fr) 2015-05-29 2018-04-11 Juno Therapeutics Inc Composition et procédés de régulation des interactions inhibitrices dans les cellules génétiquement modifiées
BR112017025813A2 (pt) 2015-06-01 2018-08-14 Univ Chicago método, kit ou composição, micróbio comensal benéfico, método para tratar ou prevenir o câncer e formulação bacteriana
US11155823B2 (en) 2015-06-15 2021-10-26 North Carolina State University Methods and compositions for efficient delivery of nucleic acids and RNA-based antimicrobials
US10648020B2 (en) 2015-06-18 2020-05-12 The Broad Institute, Inc. CRISPR enzymes and systems
US11291693B2 (en) 2015-06-25 2022-04-05 Synlogic Operating Company, Inc. Bacteria engineered to treat metabolic diseases
US20180200342A1 (en) 2015-07-13 2018-07-19 Institut Pasteur Improving sequence-specific antimicrobials by blocking dna repair
US20170216370A1 (en) 2015-07-31 2017-08-03 Synlogic, Inc. Bacteria engineered to treat disorders involving propionate catabolism
GB201514510D0 (en) 2015-08-14 2015-09-30 Nemesis Bioscience Ltd Delivery vehicle
KR102569754B1 (ko) 2015-09-10 2023-08-23 위니베르시트카솔리끄드루뱅 대사장애를 치료하기 위한 살균된 아커만시아의 용도
WO2017058751A1 (en) 2015-09-28 2017-04-06 North Carolina State University Methods and compositions for sequence specific antimicrobials
AU2016346646B2 (en) 2015-10-30 2022-12-01 Synlogic Operating Company, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
CN112569262A (zh) 2015-11-20 2021-03-30 4D制药研究有限公司 包含细菌菌株的组合物
EP3384016A4 (en) 2015-12-04 2019-04-24 Massachusetts Institute of Technology MANIPULATED PHAGEMIDES
SG11201804294WA (en) 2015-12-17 2018-07-30 Gilead Sciences Inc Tank-binding kinase inhibitor compounds
WO2017112620A1 (en) 2015-12-22 2017-06-29 North Carolina State University Methods and compositions for delivery of crispr based antimicrobials
EP3400068A1 (en) 2016-01-06 2018-11-14 Yeda Research and Development Co., Ltd. Compositions and methods for treating malignant, autoimmune and inflammatory diseases
EP3402497A1 (en) 2016-01-11 2018-11-21 Synlogic Operating Company, Inc. Bacteria engineered to treat metabolic diseases
US20190282628A1 (en) 2016-01-11 2019-09-19 Synlogic Inc. Recombinant bacteria engineered to treat diseases and disorders associated with amino acid metabolism and methods of use thereof
US20190010506A1 (en) 2016-01-11 2019-01-10 Synlogic, Inc. Bacteria engineered to treat metabolic diseases
WO2017136795A1 (en) 2016-02-04 2017-08-10 Synlogic, Inc. Bacteria engineered to treat diseases associated with tryptophan metabolism
US20170247690A1 (en) 2016-02-25 2017-08-31 Agenovir Corporation Oncoviral treatment with nuclease and chemotherapeutic
CA3016161A1 (en) 2016-03-03 2017-09-08 Cornell University Small molecule ire1-alpha inhibitors
JP7208492B2 (ja) 2016-03-10 2023-01-19 シージー オンコロジー， インコーポレイテッド 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法
EP3448400A4 (en) 2016-04-25 2019-11-13 Yale University BACTERIOPHAGE COMPOSITIONS AND USES THEREOF
WO2017193107A2 (en) 2016-05-06 2017-11-09 Juno Therapeutics, Inc. Genetically engineered cells and methods of making the same
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
CN110267651B (zh) 2016-09-27 2023-09-01 得克萨斯系统大学评议会 通过调节微生物组来增强免疫检查点阻断疗法的方法
WO2018071536A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
US10626394B2 (en) 2016-10-28 2020-04-21 Massachusetts Institute Of Technology Synthetic bacteriophages and bacteriophage compositions
WO2018112194A1 (en) 2016-12-15 2018-06-21 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating growth of a genetically modified gut bacterial cell
CA3047029A1 (en) 2016-12-22 2018-06-28 Institut Gustave Roussy Microbiota composition, as a marker of responsiveness to anti-pd1/pd-l1/pd-l2 antibodies and use of microbial modulators for improving the efficacy of an anti-pd1/pd-l1/pd-l2 ab-based treatment
US11149269B2 (en) 2017-05-15 2021-10-19 New York University Compositions and methods for non-antibiotic treating of bacterial infections by blocking or disrupting bacterial genes involved in virulence or viability
US12274720B2 (en) 2017-05-24 2025-04-15 Viktor Veniaminovich Tets Methods for treating and preventing diseases
US20200157237A1 (en) 2017-05-25 2020-05-21 The Broad Institute, Inc. Lymphocyte antigen cd5like (cd5l) monomer, homodimer, and interleukin 12b (p40) heterodimer antagonists and methods of use thereof
EP3630975B1 (en) 2017-05-26 2025-11-19 North Carolina State University Altered guide rnas for modulating cas9 activity and methods of use
US20200129570A1 (en) 2017-06-02 2020-04-30 Board Of Regents, The University Of Texas System Specific Bacterial Species and Metabolite That Improves Immune Checkpoint Inhibitor Therapy Efficacy
US11453874B2 (en) 2017-06-07 2022-09-27 The Rockefeller University Enhancement of CRISPR gene editing or target destruction by co-expression of heterologous DNA repair protein
GB201710126D0 (en) 2017-06-25 2017-08-09 Snipr Tech Ltd Vectors & Methods
GB201712733D0 (en) 2017-08-08 2017-09-20 Snipr Tech Ltd Methods & cells
US10303379B2 (en) 2017-09-25 2019-05-28 International Business Machines Corporation Efficient adaptive read-ahead in log structured storage
US20190160120A1 (en) 2017-11-29 2019-05-30 Snipr Biome Aps Dna, methods etc
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
EP3788152A4 (en) 2018-05-04 2022-03-09 Locus Biosciences, Inc. METHODS AND COMPOSITIONS FOR KILLING A TARGET BACTERIA
CA3102353A1 (en) 2018-06-19 2019-12-26 Glaxosmithkline Biologicals Sa Immunogenic composition
US12264313B2 (en) 2018-10-01 2025-04-01 North Carolina State University Recombinant type I CRISPR-Cas system and uses thereof for genome modification and alteration of expression
US12264330B2 (en) 2018-10-01 2025-04-01 North Carolina State University Recombinant type I CRISPR-Cas system and uses thereof for killing target cells
EP3861120A4 (en) 2018-10-01 2023-08-16 North Carolina State University Recombinant type i crispr-cas system
US12203123B2 (en) 2018-10-01 2025-01-21 North Carolina State University Recombinant type I CRISPR-Cas system and uses thereof for screening for variant cells
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
US20220056457A1 (en) 2018-12-11 2022-02-24 The University Of Western Ontario Cis conjugative plasmid system
KR102227515B1 (ko) 2018-12-18 2021-03-12 주식회사 포스코 제올라이트 및 그 제조방법
GB201901099D0 (en) 2019-01-27 2019-03-13 Snipr Biome Aps Methods, uses and compositions
WO2021097118A1 (en) 2019-11-12 2021-05-20 The Broad Institute, Inc. Small type ii cas proteins and methods of use thereof
US20230235361A1 (en) 2020-07-03 2023-07-27 Eligo Bioscience Method of containment of nucleic acid vectors introduced in a microbiome population
GB202015255D0 (en) 2020-09-26 2020-11-11 Snipr Biome Aps Synthetic viruses

Also Published As

Publication number Publication date
US10561148B2 (en) 2020-02-18
US20180084786A1 (en) 2018-03-29
EP4570253A3 (en) 2025-08-20
US20200267992A1 (en) 2020-08-27
US11400110B2 (en) 2022-08-02
US20250186479A1 (en) 2025-06-12
US20210290654A1 (en) 2021-09-23
US20180084785A1 (en) 2018-03-29
AU2022202944A1 (en) 2022-05-26
JP2022106717A (ja) 2022-07-20
US10506812B2 (en) 2019-12-17
JP2020058369A (ja) 2020-04-16
US20220362280A1 (en) 2022-11-17
IL293646A (en) 2022-08-01
US20210283167A1 (en) 2021-09-16
IL293646B1 (en) 2024-03-01
KR20250107283A (ko) 2025-07-11
KR102138209B1 (ko) 2020-07-28
US11844760B2 (en) 2023-12-19
SG11201708706YA (en) 2017-11-29
EP3903586A1 (en) 2021-11-03
CN107667173A (zh) 2018-02-06
US20200128832A1 (en) 2020-04-30
NZ738068A (en) 2019-07-26
US11517582B2 (en) 2022-12-06
US20190230936A1 (en) 2019-08-01
US20180070594A1 (en) 2018-03-15
US20200337313A1 (en) 2020-10-29
JP2018515138A (ja) 2018-06-14
RU2019130337A (ru) 2019-10-15
AU2016257306A1 (en) 2018-01-04
RU2017142352A3 (sl) 2019-06-06
US20190133135A1 (en) 2019-05-09
US20210145006A1 (en) 2021-05-20
EP4169383A1 (en) 2023-04-26
IL293646B2 (en) 2024-07-01
US20240082289A1 (en) 2024-03-14
EP4233546A2 (en) 2023-08-30
US20220233575A1 (en) 2022-07-28
IL255427A0 (en) 2017-12-31
EP4570253A2 (en) 2025-06-18
US11147830B2 (en) 2021-10-19
US11642363B2 (en) 2023-05-09
AU2019236694B2 (en) 2022-02-03
IL255427B (en) 2021-10-31
AU2022202944B2 (en) 2023-01-05
JP2024038120A (ja) 2024-03-19
WO2016177682A1 (en) 2016-11-10
KR20230174291A (ko) 2023-12-27
EP3711488A1 (en) 2020-09-23
US10524477B2 (en) 2020-01-07
US20180146681A1 (en) 2018-05-31
US20250228884A1 (en) 2025-07-17
US10463049B2 (en) 2019-11-05
DK3291679T3 (da) 2022-01-17
IL310108A (en) 2024-03-01
AU2023202066B2 (en) 2024-04-18
AU2016257306B2 (en) 2019-06-27
KR20200091499A (ko) 2020-07-30
IL310108B1 (en) 2025-01-01
EP3461337A1 (en) 2019-04-03
ES2905525T3 (es) 2022-04-11
EP3729967A1 (en) 2020-10-28
US20200085066A1 (en) 2020-03-19
US11547716B2 (en) 2023-01-10
KR20180002776A (ko) 2018-01-08
US20220241318A1 (en) 2022-08-04
CN114099712A (zh) 2022-03-01
EP3291679A1 (en) 2018-03-14
US10582712B2 (en) 2020-03-10
US12226430B2 (en) 2025-02-18
EP3907285A1 (en) 2021-11-10
US9701964B2 (en) 2017-07-11
AU2019236694A1 (en) 2019-10-17
US20180064115A1 (en) 2018-03-08
US11612617B2 (en) 2023-03-28
EP4545082A3 (en) 2025-07-02
US20200068901A1 (en) 2020-03-05
US20250161345A1 (en) 2025-05-22
RU2017142352A (ru) 2019-06-06
US10624349B2 (en) 2020-04-21
EP3563684A1 (en) 2019-11-06
IL283877B (en) 2022-07-01
EP4545082A2 (en) 2025-04-30
US20160333348A1 (en) 2016-11-17
AU2023202066A1 (en) 2023-05-11
US20180064114A1 (en) 2018-03-08
EP3291679B1 (en) 2021-12-15
AU2024202021A1 (en) 2024-04-18
US20200077663A1 (en) 2020-03-12
US20170246221A1 (en) 2017-08-31
CA2984975A1 (en) 2016-11-10
RU2019130337A3 (sl) 2021-12-20
US20220273696A1 (en) 2022-09-01
US20210386773A1 (en) 2021-12-16
HK1245016A1 (zh) 2018-08-24
EP4005386A1 (en) 2022-06-01
US20200205416A1 (en) 2020-07-02
US20170196225A1 (en) 2017-07-13
EP4233546A3 (en) 2023-09-27
AU2024202021B2 (en) 2025-09-25
PL3291679T3 (pl) 2022-04-25
DE112016002056T5 (de) 2018-02-08
IL283877A (en) 2021-07-29
IL310108B2 (en) 2025-05-01

Similar Documents

Publication Publication Date Title
IL283877A (en) Changing bacterial populations and microbiota adaptation
ZA201701168B (en) Antibodies, compositions, and uses
EP3235465A4 (en) Implant
EP3193752A4 (en) Matrix implant
EP3215173B8 (en) Glycopeptide compositions
EP3151692A4 (en) Brassiere
EP3128970A4 (en) Absorbent garments
EP3310314A4 (en) ARMCHAIR CHAIR
EP3372118A4 (en) CHAIR
SG11201705416XA (en) Bacterial compositions
EP3167732A4 (en) Clothing
EP3139780A4 (en) Garment
EP3165200A4 (en) Supporter
EP3243397A4 (en) Garment
EP3384793A4 (en) CLOTHING
EP3106534A4 (en) Alloy
EP3299034A4 (en) Sterilization case
EP3305956A4 (en) FABRIC
GB201402334D0 (en) Magnetic power-split
EP3175723A4 (en) Men's underwear
EP3158885A4 (en) Brassiere
EP3237399A4 (en) Compounds, compositions and methods
EP3195744A4 (en) Cooling garment
EP3139968A4 (en) Sterilizer
EP3337664A4 (en) MOUNTS